NeuroSense Therapeutics, Ltd. (Nasdaq:NRSN), an Israel-based clinical-stage biotechnology company, announced on Monday that it has entered into a collaboration agreement with Dr Ghazaleh Sadri-Vakili, MS, PhD and Massachusetts General Hospital's NeuroEpigenetics Lab.

The collaboration agreement has been signed to explore the neurotherapeutic impact of NeuroSense Therapeutics' lead combination drug, PrimeC, using a novel in vitro model generated from post-mortem ALS brain tissue (synaptoneurosomes (SNs) system).

The objective of the collaborative studies is to expand the understanding of PrimeC's mechanism of action in attenuating ALS-related pathology, specifically TDP-43 accumulation, autophagy defects, mitochondrial dysfunction, and oxidative stress. To address this, ALS- or control-SNs derived from post-mortem brains will be used to treat SH-SY5Y cells to induce reactive oxygen species and mitochondrial dysfunction, as previously shown by the Sadri-Vakili lab, in the presence or absence of PrimeC. Importantly, the studies will compare the potential therapeutic effect of PrimeC combination therapy relative to each one of its FDA-approved compounds, ciprofloxacin and celecoxib, separately, to further demonstrate the beneficial synergistic effect of PrimeC as a combination therapy.

Preliminary results from this collaboration will be presented by Dr Zimri in her talk at the upcoming AD/PD 2023 Advances in Science & Therapy Conference on 28 March - 1 April 2023 in Gothenburg, Sweden.